Skip to main content

GBM

3
Pipeline Programs
5
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
2 programs
1
1
Chlorogenic acid for InjectionPhase 2/31 trial
autologous dendritic cellsPhase 21 trial
Active Trials
NCT04115761Recruiting24Est. Dec 2026
NCT03758014Unknown200Est. Apr 2021
CANbridge Pharmaceuticals
1 program
1
CAN008Phase 21 trial
Active Trials
NCT03746288Unknown60Est. Dec 2021
BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
DCVax-LN/A
Northwest Biotherapeutics
1 program
DCVax-LN/A1 trial
Active Trials
NCT02146066Available
NaviFUS
NaviFUSTaiwan - Taipei C
1 program
NaviFUS SystemN/A1 trial
Active Trials
NCT07274787Not Yet Recruiting10Est. Jun 2029

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
BiocorpChlorogenic acid for Injection
Biocorpautologous dendritic cells
CANbridge PharmaceuticalsCAN008
NaviFUSNaviFUS System

Clinical Trials (5)

Total enrollment: 294 patients across 5 trials

NCT03758014BiocorpChlorogenic acid for Injection

Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM Patients

Start: Nov 2018Est. completion: Apr 2021200 patients
Phase 2/3Unknown
NCT04115761Biocorpautologous dendritic cells

Evaluate the Efficacy and Safety of ADCV01 As an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients

Start: Jun 2019Est. completion: Dec 202624 patients
Phase 2Recruiting

To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)

Start: Nov 2018Est. completion: Dec 202160 patients
Phase 2Unknown

Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221

N/AAvailable
NCT07274787NaviFUSNaviFUS System

Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma

Start: Jan 2026Est. completion: Jun 202910 patients
N/ANot Yet Recruiting

Related Jobs

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 294 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.